LONG TRACKING ANALYSIS ABOUT MANAGEMENT OF AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Molero, A. [1 ]
Mora, E. [2 ,3 ]
Avila, F. [4 ]
Revelles, M. [5 ]
Merchan, B. [1 ]
Regadera, A. [2 ,3 ]
Alonso, S. [4 ]
Montoro, J. [1 ]
Martin, M. [2 ,3 ]
Benlloch, L. [6 ]
Garcia, R. [5 ]
Bernal, T. [4 ]
Sanz, G. [2 ,3 ]
Valcarcel, D. [1 ]
机构：
[1] Hosp Univ Vall dHebron, Hematol, Barcelona, Spain
[2] Hosp Univ La Fe, Hematol, Valencia, Spain
[3] Politecn La Fe, Hematol, Valencia, Spain
[4] Hosp Univ Cent Asturias Oviedo, Hematol, Oviedo, Spain
[5] Hosp Univ Virgen de la Victoria, Hematol, Malaga, Spain
[6] Spanish MDS Grp, Valencia, Spain
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30219-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Oral Azacitidine in Patients With Myelodysplastic Syndrome
    Shibusawa, Motoharu
    Kidoguchi, Keisuke
    Tanimoto, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3091 - +
  • [2] Azacitidine in the management of patients with myelodysplastic syndromes
    Khan, Cyrus
    Pathe, Neeta
    Fazal, Salman
    Lister, John
    Rossetti, James M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (06) : 355 - 373
  • [3] Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis
    Juvvadi, R.
    Rossetti, J. M.
    Shadduck, R. K.
    Kaplan, R. B.
    Kennedy, M.
    Kramer, W.
    Lister, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Extreme Thrombocytosis Under Azacitidine in Patients with Myelodysplastic Syndrome
    Kelaidi, Charikleia
    Kokkinidis, Dimitrios
    Protopappa, Maria
    Papaioannou, Georgios
    Batsis, Ioannis
    Apostolou, Chrysa
    Stamatopoulos, Kostas
    Athanasiadou, Anastasia
    Anagnostopoulos, Achilles
    Vadikoliou, Chrysanthi
    BLOOD, 2012, 120 (21)
  • [5] Azacitidine for the treatment of myelodysplastic syndrome
    Cataldo, Vince D.
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 875 - 884
  • [6] Azacitidine (Vidaza) for myelodysplastic syndrome
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1201): : 11 - 11
  • [7] Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ritchie, Ellen K.
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 165 - 173
  • [8] Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
    Borthakur, Gautam
    El Ahdab, Samih
    Ravandi, Farhad
    Faderl, Stefan
    Ferrajoli, Alessandra
    Newman, Beth
    Issa, Jean-Pierre
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 690 - 695
  • [9] Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin J.
    Odenike, Olatoyosi
    Watson, Anne-Marie
    Krishnadasan, Ravi
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Hogdal, Leah
    Zhou, Ying
    Hoffman, David
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [10] A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome
    Yalniz, Fevzi Firat
    Daver, Naval
    Rezvani, Katayoun
    Kornblau, Steven
    Ohanian, Maro
    Borthakur, Gautam
    DiNardo, Courtney D.
    Konopleva, Marina
    Burger, Jan
    Gasior, Yvonne
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 658 - +
12345